Table 1.
Naltrexone Group (N = 1,138) | Alcohol Controls (N = 3,411) | P-value1 | Non-Alcohol Controls (N = 3,410) | P-value2 | |
---|---|---|---|---|---|
Gender (%) | |||||
Male | 61.6% | 62% | 0.9965 | 62% | 0.9936 |
Female | 38.4% | 38% | 0.9955 | 38% | 0.9919 |
Mean Age (SD) | 44.9 (10.6) | 44.6 (11.5) | 0.4000 | 44.8 (11.0) | 0.6804 |
Geographic Region (%) | |||||
Northeast | 24.3% | 24.3% | 0.9982 | 24.2% | 0.9799 |
North Central | 36.4% | 36.4% | 0.9941 | 36.4% | 0.9921 |
South | 26.8% | 25.7% | 0.9921 | 25.8% | 0.9934 |
West | 13.6% | 13.6% | 0.9964 | 13.6% | 0.9952 |
Relationship to Primary Insured (%) | |||||
Self (Insured Employee) | 60.2% | 64.4% | 0.4629 | 65.0% | 0.4016 |
Spouse | 33.7% | 26.6% | 0.0716 | 29.7% | 0.3247 |
Child/Other | 6.2% | 9.1% | 0.1382 | 5.4% | 0.6488 |
Insurance Plan Type (%) | |||||
Capitated | 27.8% | 30.7% | 0.4463 | 28.7% | 0.7991 |
Non-Capitated | 71.9% | 69.2% | 0.6551 | 71.1% | 0.8919 |
Missing/Unknown | 0.4% | 0.1% | 0.4335 | 0.2% | 0.6995 |
Index Year (%) | |||||
2000 | 12.6% | 12.7% | 0.9965 | 12.7% | 0.9954 |
2001 | 26.5% | 26.4% | 0.9987 | 26.4% | 0.9813 |
2002 | 30.0% | 30.0% | 0.9946 | 30.0% | 0.9929 |
2003 | 25.0% | 25.0% | 0.9951 | 25.0% | 0.9935 |
2004 | 6.0% | 5.9% | 0.9757 | 6.0% | 0.9968 |
Charlson Comorbidity Index (CCI) Mean (SD) | |||||
Pre-Index Period | 0.54 (1.01) | 0.44 (1.10) | 0.0026 | 0.21 (0.72) | < 0.0001 |
Post-Index Period | 0.58 (1.20) | 0.76 (1.47) | < 0.0001 | 0.23 (0.80) | < 0.0001 |
Chronic Disease Score (CDS) Mean (SD) | |||||
Pre-Index Period | 1.44 (1.89) | 0.98 (1.72) | < 0.0001 | 0.58 (1.33) | < 0.0001 |
Post-Index Period | 0.91 (1.67) | 0.97 (1.74) | 0.2582 | 0.51 (1.25) | < 0.0001 |
Comparison of Naltrexone Group and Alcohol Controls
Comparison of Naltrexone Group and Non-Alcohol Controls